Harrow (HROW) is partnering with a subsidiary of privately held Nordic Group for the launch of an authorized generic of Maxitrol ophthalmic suspension to treat bacterial eye infections.
Financial terms of the partnership were not disclosed.
Harrow has sold Maxitrol in the US since obtaining commercial rights to the combination of neomycin and polymyxin B sulfate and dexamethasone from Novartis (NVS) in December 2021.
Maxitrol and generic equivalents had annual sales of $20.8 million in the US, according to IQVIA data, as of January.
Harrow shares recently were trading about 1.3% higher on Thursday.
Price: 24.15, Change: +0.32, Percent Change: +1.34
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.